Edgar Filing: GOLDBERG MICHAEL B - Form 4

GOLDBERG	6 MICHAEL I	В									
Form 4	2005										
December 02									OMB A	PPROVAL	
FORM	4 UNITE	CD STATES					NGE (COMMISSION	OMB	3235-0287	
Check thi	s box		vvas	hington,	D.C. 20	549			Number:	January 31,	
if no longer subject to Section 16. Form 4 or				SECUR	ITIES				Expires: Estimated a burden hou response	2005 average irs per	
Form 5 obligatior may conti <i>See</i> Instru 1(b).	inue. Section	17(a) of the		ility Hold	ling Con	ipany	Act of	e Act of 1934, f 1935 or Section 40	n		
(Print or Type R	Responses)										
1. Name and A Connors Jan	ddress of Report	ing Person <u>*</u>	Symbol	Name and PHARMA				5. Relationship of Issuer	Reporting Per	son(s) to	
				NGS INC			5	(Check all applicable)			
(Last) (First) (Middle) 3. Date of (Month/Da				Earliest Transaction				Director Officer (give		% Owner er (specify	
C/O KELSC PARK AVE) & COMPAN NUE	IY, 320	11/30/20	-				below)	below)		
				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting 			
NEW YORE	K, NY 10022							Person	nore than One R	eporting	
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Securi	ities Acc	uired, Disposed of	, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)		2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price				Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock, par value \$.01 per share (1)	11/30/2005			Х	81	D	\$ 2.42	15,808,027	I	By Endo Pharma LLC (2) (3)	
Common Stock, par value 01 per share (1)	11/30/2005			Х	304	D	\$ 2.42	15,807,723	I	By Endo Pharma LLC (2) (3)	
Common Stock, par value \$ 01	11/30/2005			Х	291	D	\$3	15,807,432	Ι	By Endo Pharma	

Edgar Filing: GOLDBERG MICHAEL B - Form 4

per share (1)							
Common Stock, par value $\$.01$ 11/30/2005 per share (1)	X	329	D	\$ 3	15,807,104	Ι	By Endo Pharma LLC (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	tionof Derivative		urities quired or posed D) str. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	11/30/2005		Х		81	10/13/2005	08/26/2007	Common Stock	81
Call Option (obligation to sell)	\$ 2.42	11/30/2005		Х		304	10/13/2005	08/26/2007	Common Stock	304
Call Option (obligation to sell)	\$ 3	11/30/2005		Х		291	10/13/2005	08/26/2007	Common Stock	291
Call Option (obligation to sell)	\$ 3	11/30/2005		Х		329	10/13/2005	08/26/2007	Common Stock	329

Reporting Owners

Reporting Owner Name / Address

Relationships

Edgar Filing: GOLDBERG MICHAEL B - Form 4

Other

	Director	10% Owner	Officer
Connors James J II C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		Х	
NICKELL FRANK T C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	,	Х	
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	,	Х	
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	,	Х	
WALL THOMAS R IV C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	,	Х	
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	Х	
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		Х	
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		Х	
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	Х	
Loverro Frank J 320 PARK AVENUE NEW YORK, NY 10022		Х	
Signatures			
/s/James J. Connors, II	12/02/2005		

Date

<u>**</u> Signature of	
Reporting Person	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Kelso Partners V, L.P. ("KP V") is the designated filer.

KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC

- (2) status as a intenset of Endo Finama EEC. KLV shares investment and voting power along with the other intensets of Endo Finama EEC.
 (2) with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.
- Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by(3) virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.